Executive Summary
Three contract deobligations totaling $1,236,299,978 in obligations highlight funded backlogs in civilian IT services, with 1/3 defense-related (VA) and 2/3 pure civilian (GSA, State Department), dominated by large IT delivery orders to Leidos ($543.6M) and Oracle Health ($519.0M).
Highest-conviction bullish signal is Oracle's $519.0M VA EHRM operations award (strength 7/10, materiality 8/10), signaling multi-year VA IT stability through 2027 despite $0 outlay. Leidos' $543.6M GSA IT contract adds mature backlog upside to $729.6M, while BL Harbert's $173.7M State Department construction remains neutral. Key risk is stalled execution with Leidos' negative $-1.7M outlay and $0 progress on Oracle/BL Harbert, vulnerable to deobligation in a CR environment. Watch outlay ramps and option exercises across all three into FY2026-2027.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Contract Deobligations Alert digest from April 10, 2026.
Investment Signals (3)
- Leidos $543.6M GSA IT Delivery Order Signals Funded Backlog (MEDIUM)▲
Leidos' $543.6M cost-plus award fee delivery order (potential $729.6M with options) under GSA FAS provides ~$83.6M annual revenue est. through 2024, with $187.4M subawards across 1090 recipients despite $-1.7M outlay.
- Oracle Health $519.0M VA EHRM Contract Builds Multi-Year Backlog (HIGH)▲
Oracle Health Government Services' $519.0M firm fixed price delivery order (potential $632.8M with options) for VA EHRM operations through 2027 offers ~$104M annual revenue est., with $12.5M subawards despite $0 outlay.
- BL Harbert $173.7M State Department Construction Holds Steady (LOW)▲
BL Harbert International's $173.7M firm fixed price contract for Podgorica Montenegro project through 2027 equates to ~$23.1M annual revenue est., with $5.5M subawards across 47 recipients and $0 outlay.
Risk Flags (2)
- Execution [HIGH RISK]▼
Leidos GSA contract shows negative $-1.7M total outlay on $543.6M obligation, signaling potential deobligation or spending halt near 2024 end date.
- Execution [HIGH RISK]▼
Oracle VA and BL Harbert State contracts both at $0 outlay ($519.0M and $173.7M obligations), with high firm fixed price risk amid deobligation alert.
Opportunities (2)
- ◆
Leidos GSA IT order options could add $185.95M to reach $729.6M total via cost-plus structure.
- ◆
Oracle VA EHRM delivery order options could expand $519.0M obligation to $632.8M through 2027.
Sector Themes (1)
- ◆
Leidos ($543.6M GSA) and Oracle ($519.0M VA) represent $1.06B in IT delivery orders (NAICS 541512) with funded obligations but minimal outlays, signaling backlog durability in GSA/VA despite deobligation risks.
Watch List (3)
- 👁
{"entity"=>"Leidos Holdings, Inc.", "reason"=>"Track $-1.7M outlay reversal and options to $729.6M on $543.6M GSA IT contract through 2024-02-29.", "trigger"=>"outlay progress, option exercise"}
- 👁
{"entity"=>"Oracle Corporation", "reason"=>"$0 outlay on $519.0M VA EHRM contract with $632.8M potential; highest materiality (8/10).", "trigger"=>"outlay start, 2027-04-10 performance"}
- 👁
{"entity"=>"BL Harbert International LLC", "reason"=>"$0 outlay on $173.7M State construction through 2027-03-25.", "trigger"=>"outlay progress"}
Get daily alerts with 3 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 3 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Contract Deobligations Alert
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals